SEC Form 4 · accession 0002109966-26-000004
NovaBridge Biosciences · NBP
Statement of changes in beneficial ownership, as filed. Original on EDGAR ↗
Reporting owner
Sean Wuxiong Cao
Officer — Chief Bus. Development Officer · Director
Period of report
Jun 22, 2026
Accepted (ET)
Jun 24, 2026 · 7:22 pm EDT
Rule 10b5-1 plan
box not checked
Issuer CIK
0001778016
Table I — non-derivative securities
No Table I lines on this filing.
Table II — derivative securities
| Security | Conv. / exercise price | Date | Code | Shares | A/D | Exercisable | Expires | Underlying | Underlying shares | Owned after | D/I |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Restricted Share UnitsF2,F1,F3,F4 | — | Jun 22, 2026 | A | 181,280 | A | — | — | Ordinary Shares | 181,280 | 181,280 | D |
| 2025 Employee Share Option (right to buy)F2,F5,F4 | $1.53 | Jun 22, 2026 | A | 181,290 | A | — | Jun 22, 2036 | Ordinary Shares | 181,290 | 181,290 | D |
Explanation of responses
- F1Each restricted stock unit ("RSU") represents a contingent right to receive one American Depositary Shares ("ADS").
- F2Number of underlying securities and exercise price expressed in terms of ADSs.
- F3The RSUs shall vest over four years, with one-fourth vesting on September 3, 2026 and the balance vesting ratably over the subsequent 12 quarters on the third day of each third month.
- F4The Ordinary Shares may be represented by ADSs. Each 10 ADSs represent 23 Ordinary Shares of the Issuer.
- F5The option vests, if at all, in eight equal quarterly installments following the date on which the 30-trading-day weighted average price of the Issuer's ADS (based on trading days only) is at or above US$8.00.